Our findings suggest that MAP3K3 is a promising target for alleviating drug resistance and that combination treatment with ponatinib with inhibitors of BRAF or CDK4/6 should be further tested as a YAP-targeting strategy in cancer treatment. Here, BRAF is linked to cancer.